1. Wu Y, Wu J, Chen T, et al.
Fusobacterium nucleatum potentiates intestinal tumorigenesis in mice via a Toll-like receptor 4/p21-activated kinase 1 cascade. Dig Dis Sci. 2018; 63:1210–8.
Article
2. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013; 14:207–15.
3. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016; 65:330–9.
Article
4. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22:292–8.
5. Castellarin M, Warren RL, Freeman JD, et al.
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012; 22:299–306.
Article
6. Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015; 137:1258–68.
7. McCoy AN, Araujo-Perez F, Azcarate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013; 8:e53653.
8. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW.
Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; 14:195–206.
Article
9. Abed J, Emgard JE, Zamir G, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016; 20:215–25.
10. Yang Y, Weng W, Peng J, et al.
Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factorkappaB, and up-regulating expression of microRNA-21. Gastroenterology. 2017; 152:851–66.
Article
11. Yu T, Guo F, Yu Y, et al.
Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017; 170:548–63.
Article
12. Mandip KC, Steer CJ. Novel mechanisms of chemoresistance by Fusobacterium nucleatum involve not so novel pathways of microRNAs and autophagy. Transl Cancer Res. 2018; 7(Suppl 1):S10–5.
13. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of
Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017; 358:1443–8.
Article
14. Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016; 7:46158–72.
Article
15. Yamaoka Y, Suehiro Y, Hashimoto S, et al.
Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018; 53:517–24.
Article
16. Yan X, Liu L, Li H, Qin H, Sun Z. Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. Onco Targets Ther. 2017; 10:5031–46.
17. Oh HJ, Kim JH, Bae JM, Kim HJ, Cho NY, Kang GH. Prognostic impact of
Fusobacterium nucleatum depends on combined tumor location and microsatellite instability status in stage II/III colorectal cancers treated with adjuvant chemotherapy. J Pathol Transl Med. 2019; 53:40–9.
Article
18. Sakamoto Y, Mima K, Daitoku N, et al. Fusobacterium nucleatum in colorectal cancer liver metastasis and patient prognosis. Cancer Sci. 2018; 109:1360.
19. Chernyavskiy P, Kennerley VM, Jemal A, Little MP, Rosenberg PS. Heterogeneity of colon and rectum cancer incidence across 612 SEER counties, 2000-2014. Int J Cancer. 2019; 144:1786–95.
Article
20. de Carvalho AC, de Mattos Pereira L, Datorre JG, et al. Microbiota profile and impact of Fusobacterium nucleatum in colorectal cancer patients of Barretos Cancer Hospital. Front Oncol. 2019; 9:813.
21. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into metaanalysis. Trials. 2007; 8:16.
Article
22. Sun Y, An QM, Tian XY, et al. Fusobacterium nucleatum infection is correlated with tumor metastasis and postoperative survival of colorectal cancer patients in China. Transl Cancer Res. 2016; 5:579–88.
23. Kunzmann AT, Proenca MA, Jordao HW, et al.
Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients. Eur J Clin Microbiol Infect Dis. 2019; 38:1891–9.
Article
24. Chen Y, Lu Y, Ke Y, Li Y. Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers. Medicine (Baltimore). 2019; 98:e17221.
25. Mima K, Sukawa Y, Nishihara R, et al.
Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015; 1:653–61.
Article
26. Chen Y, Chen Y, Zhang J, et al. Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics. 2020; 10:323–39.
Article
27. Wang S, Liu Y, Li J, et al. Fusobacterium nucleatum acts as a procarcinogenic bacterium in colorectal cancer: from association to causality. Front Cell Dev Biol. 2021; 9:710165.
28. Zhang S, Yang Y, Weng W, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019; 38:14.
29. Bae JM, Kim JH, Kang GH. Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med. 2016; 140:406–12.
Article
30. Wen X, Jeong S, Kim Y, et al. Improved results of LINE-1 methylation analysis in formalin-fixed, paraffin-embedded tissues with the application of a heating step during the DNA extraction process. Clin Epigenetics. 2017; 9:1.
Article
31. Freifelder D, Davison PF. Physicochemical studies on the reaction between formaldehyde and DNA. Biophys J. 1963; 3:49–63.
Article
32. Imrit K, Goldfischer M, Wang J, et al. Identification of bacteria in formalin-fixed, paraffin-embedded heart valve tissue via 16S rRNA gene nucleotide sequencing. J Clin Microbiol. 2006; 44:2609–11.
Article
33. Gethings-Behncke C, Coleman HG, Jordao HWT, et al. Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2020; 29:539–48.
34. Huangfu SC, Zhang WB, Zhang HR, et al. Clinicopathological and prognostic significance of Fusobacterium nucleatum infection in colorectal cancer: a meta-analysis. J Cancer. 2021; 12:1583–91.